4-甲基-2-(2-噻吩)-1,3-噻唑-5-羧酸 | 209540-08-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基-2-(2-噻吩)-1,3-噻唑-5-羧酸
• 中文别名: 4-甲基-2-(2-噻吩基)-1,3-噻唑-5-甲酸
• 英文名称: 2-(thiophen-2-yl)-4-methyl-thiazole-5-carboxylic acid
• 英文别名: 4-methyl-2-(thien-2-yl)-1,3-thiazol-5-carboxylic acid；4-methyl-2-(2-thienyl)-1,3-thiazol-5-carboxylic acid；4-Methyl-2-(2-thienyl)-1,3-thiazole-5-carboxylic acid；4-methyl-2-thiophen-2-yl-1,3-thiazole-5-carboxylic acid
• CAS: 209540-08-9
• 化学式: C₉H₇NO₂S₂
• mdl: MFCD01936004
• 分子量: 225.292
• InChiKey: DSMGYNWKEJBPKW-UHFFFAOYSA-N

物化性质

• 熔点：
  233-235°
• 沸点：
  441.2±53.0 °C(Predicted)
• 密度：
  1.446±0.06 g/cm3(Predicted)
• 溶解度：
  >33.8 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934999090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  4-甲基-2-(2-噻吩)-1,3-噻唑-5-羧酸 生成 3-{4-Methoxy-3-[({[4-methyl-2-(thien-2-yl)-1,3-thiazol-5-yl]carbonyl}amino)methyl]phenyl}benzoic acid
  参考文献：
  名称：

  EP1394147

  摘要：

  公开号：

文献信息

• Inhibitors of P2X3
  申请人：Brotherton-Pleiss E. Christine

  公开号：US20070037974A1

  公开（公告）日：2007-02-15

  Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders: wherein R 1 is —C(═S)CH 3 , pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R 2a and R 2b are independently H, methyl, or ethyl; R 3 is H or methyl; Y is a bond, —(CR 4 R 5 ) n — or —CR 4 ═CR 5 —; wherein R 4 and R 5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R 6 , R 7 and R 8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R 6 and R 7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R 1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.

  式1的化合物是P2X3的调节剂，用于治疗疼痛和泌尿生殖、胃肠和呼吸系统疾病： 其中 R 1 为—C(═S)CH 3 ，吡啶基，嘧啶基，吡嗪基，噻唑基，呋喃基，呋喃甲酰基，乙酰基或氨基甲酰基；R 2a 和R 2b 独立地为H，甲基或乙基；R 3 为H或甲基；Y为键，—(CR 4 R 5 ) n —或—CR 4 ═CR 5 —；其中R 4 和R 5 各自独立地为H或甲基，n为1或2；X为N或CH；A为苯基，5-成员杂环基或6-成员杂环基；R 6 ，R 7 和R 8 各自独立地为H，卤素，低碳基，环烷基，烷基硫醚，烷基硫醚-低碳基，烷基磺酰基-低碳基，二(低碳基)氨基-低碳基，吗啉基-低碳基，4-甲基哌嗪基-甲基，三氟甲基，吡啶基，四唑基，噻吩基，苯基，联苯基或苄基（其中噻吩基，苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基或低烷硫基取代）或R 6 和R 7 一起形成一个被0-3个取自由低碳基，低烷氧基，氧代基，卤素，噻吩基-低碳基，苯基，苄基（其中苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基，低烷硫基，氨基-低碳基，烷基氨基-低碳基或二(低碳基)氨基-低碳基取代）的5-成员或6-成员碳环或杂环取代环；及其药学上可接受的盐；其中当R 1 为嘧啶-2-基时，X为N，Y为键，A为噁唑-5-基时，所述噁唑-5-基中位置4的碳原子在所述噁唑-5-基中位置2的碳原子被取代的苯基取代时不被丙基取代，且所述噁唑-5-基中位置4的碳原子在位置2被取代的苯基取代时不被苯基取代。
• HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR
  申请人：Uchida Hiroshi

  公开号：US20130079306A1

  公开（公告）日：2013-03-28

  A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

  提供了一种新型杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式（1）表示：其中A代表烷基、环烷基、芳基或杂环基，基团A可能有取代基；环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环，环B可能有取代基；环C代表芳香环，环C可能有取代基；L代表包含3至5个原子的主链的连接物，所述原子选自碳原子、氮原子、氧原子和硫原子组成的群，其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子，连接物L可能有取代基；n为0或1。
• Carboxylic acid derivative and medicine comprising salt or ester of the same
  申请人：——

  公开号：US20040214888A1

  公开（公告）日：2004-10-28

  The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: 1 (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including —NR X1 CQ 1 O— (wherein Q 1 represents an oxygen atom or a sulfur atom; R X1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups), ONR X1 CQ 1 —, —NR X1 CQ 1 —, —CQ 1 NR X1 —, —NR X1a CQ 1 NR X1b —, —Q 2 SO 2 — and —SO 2 Q 2 —; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.

  本发明提供了一种新型羧酸衍生物，可用作胰岛素增敏剂，其盐或其水合物，以及包含该衍生物作为活性成分的药物。具体而言，本发明提供了一种由以下式子表示的羧酸衍生物：1（其中L表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；M表示单键，或C1至C6烷基，C2至C6烯基或C2至C6炔基，每个基团都可以有一个或多个取代基；T表示单键，或C1至C3烷基，C2至C3烯基或C2至C3炔基，每个基团都可以有一个或多个取代基；W表示羧基；X表示单键，氧原子，或由各种取代基表示的基团，包括-NRX1CQ1O-（其中Q1表示氧原子或硫原子；RX1表示氢原子，氰基，甲酰基或各种基团，包括C1至C6烷基和C1至C6羟基烷基，每个基团都可以有一个或多个取代基），ONRX1CQ1-，-NRX1CQ1-，-CQ1NRX1-，-NRX1aCQ1NRX1b-，-Q2SO2-和-SO2Q2-；Y表示一个具有1个或多个取代基和1个或多个杂原子的5至14环芳基，或一个C3至C7脂环烃基；环Z和环U可以相同或不同，每个环表示一个具有1至4个取代基和1个或多个杂原子的5至14环芳基，环可能部分饱和），其盐，酯或其水合物。
• CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME
  申请人：Eisai Co., Ltd.

  公开号：EP1394147A1

  公开（公告）日：2004-03-03

  The present invention provides novel carboxylic acid derivatives useful as an insulin sensitizer, a salt thereof or a hydrate of them, and a medicament comprising the derivative as the active ingredient. Specifically, it provides a carboxylic acid derivative represented by the following formula: (wherein L represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; M represents a single bond, or a C1 to C6 alkylene group, a C2 to C6 alkenylene group or a C2 to C6 alkynylene group, each of which may have one or more substituent groups; T represents a single bond, or a C1 to C3 alkylene group, a C2 to C3 alkenylene group or a C2 to C3 alkynylene group, each of which may have one or more substituent groups; W represents a carboxyl group; X represents a single bond, an oxygen atom, or a group represented by the various substituent groups including -NRX1CQ1O- (wherein Q1 represents an oxygen atom or a sulfur atom; RX1 represents a hydrogen atom, a cyano group, a formyl group, or various groups including a C1 to C6 alkyl group and a C1 to C6 hydroxyalkyl group, each of which may have one or more substituent groups) , ONRX1CQ1-, -NRX1CQ1-, -CQ1NRX1-, -NRX1aCQ1NRX1b-, -Q2SO2- and -SO2Q2-; Y represents a 5 to 14-membered aromatic group which may have one or more substituent groups and one or more hetero atoms, or a C3 to C7 alicyclic hydrocarbon group; and the rings Z and U may be the same as or different from each other and each represents a 5 to 14-membered aromatic group which may have 1 to 4 substituent groups and one or more hetero atoms, and the ring may be partially saturated.), a salt thereof, an ester thereof or a hydrate of them.

  本发明提供了可用作胰岛素增敏剂的新型羧酸衍生物、其盐或水合物，以及以该衍生物为活性成分的药物。具体地说，它提供了由下式表示的羧酸衍生物： (其中 L 代表单键，或 C1 至 C6 亚烷基、C2 至 C6 烯基或 C2 至 C6 亚炔基，其中每个基团可具有一个或多个取代基；M 代表单键，或 C1 至 C6 亚烷基、C2 至 C6 烯基或 C2 至 C6 亚炔基，其中每个基团可具有一个或多个取代基；T 代表单键，或 C1 至 C3 亚烷基、C2 至 C3 烯基或 C2 至 C3 亚炔基，其中每个基团可带有一个或多个取代基； W 代表羧基； X 代表单键、氧原子或由各种取代基团代表的基团，包括 -NRX1CQ1O- （其中 Q1 代表氧原子或硫原子；RX1 代表氢原子、氰基、甲酰基或包括 C1 至 C6 烷基和 C1 至 C6 羟烷基在内的各种基团，其中每个基团可具有一个或多个取代基）、 ONRX1CQ1-、-NRX1CQ1-、-CQ1NRX1-、-NRX1aCQ1NRX1b-、-Q2SO2- 和 -SO2Q2-；Y 代表 5 至 14 元芳香基团，可带有一个或多个取代基团和一个或多个杂原子，或 C3 至 C7 脂环烃基团；且环 Z 和 U 可彼此相同或不同，且各自代表 5 至 14 元芳香基团，可带有 1 至 4 个取代基团和一个或多个杂原子，且环可为部分饱和。)、其盐、其酯或它们的水合物。
• EP1093367A4
  申请人：——

  公开号：EP1093367A4

  公开（公告）日：2003-03-05